Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease.
Although we and others have demonstrated that neural stem cells (NSCs) may impact such neurogenetic conditions as lysosomal storage diseases when transplanted at birth, it has remained unclear whether such interventions can impact well-established mid-stage disease, a situation often encountered cli...
| Հիմնական հեղինակներ: | , , , , , , , , , , |
|---|---|
| Ձևաչափ: | Journal article |
| Լեզու: | English |
| Հրապարակվել է: |
2009
|
| _version_ | 1826258595688218624 |
|---|---|
| author | Jeyakumar, M Lee, J Sibson, N Lowe, J Stuckey, D Tester, K Fu, G Newlin, R Smith, D Snyder, E Platt, F |
| author_facet | Jeyakumar, M Lee, J Sibson, N Lowe, J Stuckey, D Tester, K Fu, G Newlin, R Smith, D Snyder, E Platt, F |
| author_sort | Jeyakumar, M |
| collection | OXFORD |
| description | Although we and others have demonstrated that neural stem cells (NSCs) may impact such neurogenetic conditions as lysosomal storage diseases when transplanted at birth, it has remained unclear whether such interventions can impact well-established mid-stage disease, a situation often encountered clinically. Here we report that when NSCs were injected intracranially into the brain of adult symptomatic Sandhoff (Hexb(-/-)) mice, cells migrated far from the injection site and integrated into the host cytoarchitecture, restoring beta-hexosaminidase enzyme activity and promoting neuropathologic and behavioral improvement. Mouse lifespan increased, neurological function improved, and disease progression was slowed. These clinical benefits correlated with neuropathological correction at the cellular and molecular levels, reflecting the multiple potential beneficial actions of stem cells, including enzyme cross-correction, cell replacement, tropic support, and direct anti-inflammatory action. Pathotropism (i.e., migration and homing of NSCs to pathological sites) could be imaged in real time by magnetic resonance imaging. Differentially expressed chemokines might play a role in directing the migration of transplanted stem cells to sites of pathology. Significantly, the therapeutic impact of NSCs implanted in even a single location was surprisingly widespread due to both cell migration and enzyme diffusion. Because many of the beneficial actions of NSCs observed in newborn brains were recapitulated in adult brains to the benefit of Sandhoff recipients, NSC-based interventions may also be useful in symptomatic subjects with established disease. |
| first_indexed | 2024-03-06T18:36:28Z |
| format | Journal article |
| id | oxford-uuid:0b6a5dd1-ee19-4020-92e6-01730f89a82f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:36:28Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:0b6a5dd1-ee19-4020-92e6-01730f89a82f2022-03-26T09:29:12ZNeural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0b6a5dd1-ee19-4020-92e6-01730f89a82fEnglishSymplectic Elements at Oxford2009Jeyakumar, MLee, JSibson, NLowe, JStuckey, DTester, KFu, GNewlin, RSmith, DSnyder, EPlatt, FAlthough we and others have demonstrated that neural stem cells (NSCs) may impact such neurogenetic conditions as lysosomal storage diseases when transplanted at birth, it has remained unclear whether such interventions can impact well-established mid-stage disease, a situation often encountered clinically. Here we report that when NSCs were injected intracranially into the brain of adult symptomatic Sandhoff (Hexb(-/-)) mice, cells migrated far from the injection site and integrated into the host cytoarchitecture, restoring beta-hexosaminidase enzyme activity and promoting neuropathologic and behavioral improvement. Mouse lifespan increased, neurological function improved, and disease progression was slowed. These clinical benefits correlated with neuropathological correction at the cellular and molecular levels, reflecting the multiple potential beneficial actions of stem cells, including enzyme cross-correction, cell replacement, tropic support, and direct anti-inflammatory action. Pathotropism (i.e., migration and homing of NSCs to pathological sites) could be imaged in real time by magnetic resonance imaging. Differentially expressed chemokines might play a role in directing the migration of transplanted stem cells to sites of pathology. Significantly, the therapeutic impact of NSCs implanted in even a single location was surprisingly widespread due to both cell migration and enzyme diffusion. Because many of the beneficial actions of NSCs observed in newborn brains were recapitulated in adult brains to the benefit of Sandhoff recipients, NSC-based interventions may also be useful in symptomatic subjects with established disease. |
| spellingShingle | Jeyakumar, M Lee, J Sibson, N Lowe, J Stuckey, D Tester, K Fu, G Newlin, R Smith, D Snyder, E Platt, F Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. |
| title | Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. |
| title_full | Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. |
| title_fullStr | Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. |
| title_full_unstemmed | Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. |
| title_short | Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. |
| title_sort | neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease |
| work_keys_str_mv | AT jeyakumarm neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT leej neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT sibsonn neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT lowej neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT stuckeyd neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT testerk neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT fug neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT newlinr neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT smithd neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT snydere neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease AT plattf neuralstemcelltransplantationbenefitsamonogenicneurometabolicdisorderduringthesymptomaticphaseofdisease |